Acquired Immuno Deficiency Syndrome Market Size – Industry Structure Evaluation, Demand Drivers Analysis, Regional Growth Analysis and Identification, Competitive Positioning Review & Global Market Size Forecast to 2032
5.9%
CAGR (2026-2032)
38.29 USD Bn.
Market Size
315
Report Pages
138
Market Tables
Overview
The Acquired Immuno Deficiency Syndrome Market size was valued at USD 38.29 Billion in 2025 and the total Acquired Immuno Deficiency Syndrome revenue is expected to grow at a CAGR of 5.9% from 2025 to 2032, reaching nearly USD 57.20 Billion by 2032.
Acquired Immuno Deficiency Syndrome Market overview:
Acquired Immuno Deficiency Syndrome (AIDS) is a disease caused by HIV which affects the immune system, leaving the body vulnerable to life-threatening infections & cancers. AIDS is the most advanced stage of HIV infection. The Centers for disease control has defined AIDS as beginning when a person with HIV infection has CD4 cell, also called as “T-cell” count below 200.
To know about the Research Methodology :- Request Free Sample Report
The risk of progression to AIDS decreases by using highly effective antiretroviral therapy (ART) regimens. ART improves the immune system of the patient & substantially increases life expectancy. R&D of various novel drugs that can prove to be a long term cure for HIV and can suppress it throughout the life of an individual. Approval of these new drugs can drive the market during the forecast period. Increasing government initiatives to create awareness regarding HIV/AIDS and its treatment are aiding the growth of this market. However, the stigma attached to HIV/AIDS testing & treatment and the associated adverse effects of some HIV/AIDS drugs are the restraint factors limiting the growth of the market.
Acquired Immuno Deficiency Syndrome Market Segment Analysis:
The NRTIs segment holds up to 40% of the market share. NRTIs inhibit reverse transcriptase activity and ultimately arrest viral replication.
The objective of the report is to present a comprehensive analysis of the Global Acquired Immuno Deficiency Syndrome Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers.
The report also helps in understanding Global Acquired Immuno Deficiency Syndrome Market dynamics, structure by analyzing the market segments and project the Global Acquired Immuno Deficiency Syndrome Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Acquired Immuno Deficiency Syndrome Market make the report investor’s guide.
Acquired Immuno Deficiency Syndrome Market Regional Insights:
North America holds the largest market share owing to the presence of key market players and high healthcare expenditure. A large number of R&D initiatives for new drugs are propelling the growth of the market in North America. Following North America, Europe and APAC also hold the largest share in the global market owing to the rising patient pool. APAC countries like India and China are expected to demonstrate comparatively higher CAGR due to the increasing number of patients, during the forecast period.
Acquired Immuno Deficiency Syndrome Market Scope
:Inquire before buying
| Global Acquired Immuno Deficiency Syndrome Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2032 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | USD 38.29 Bn. |
| Forecast Period 2026 to 2032 CAGR: | 5.9% | Market Size in 2032: | USD 57.20 Bn. |
| Segments Covered: | by Drug Class | Nucleoside Reverse Transcriptase Inhibitors(NRTIs) Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Combination Class Drugs Entry & fusion inhibitors integrase inhibitors |
|
| by Disease | Genetic Disorders Rare cancers Rare Blood Disorders Autoimmune Disorders Infectious Diseases |
||
Acquired Immuno Deficiency Syndrome Market, by Region
North America (United States, Canada, and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, and the Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, ASEAN, Indonesia, Philippines, Malaysia, Vietnam, Thailand, ASEAN, Rest of Asia Pacific)
Middle East & Africa (South Africa, GCC, Nigeria, Rest of ME&A)
South America (Brazil, Argentina, Rest of South America)
Acquired Immuno Deficiency Syndrome (AIDS) Market Key players:
1. Shire Plc.
2. AstraZeneca
3. Eli Lilly and Company
4. Merck KGaA
5. Sanofi
6. Pfizer
7. Amgen Inc.
8. Biogen
9. Novartis AG
10. Actelion
11. Daiichi Sankyo
12. Boehringer Ingelheim International GmbH
13. Cipla Inc.
14. AbbVie Inc.
15. Bristol-Myers Squibb company
16. Teva Pharmaceuticals
Frequently Asked Questions:
1. Which region has the largest share in Global Market?
Ans: North America region holds the highest share in 2025.
2. What is the growth rate of Global Market?
Ans: The Global Market is growing at a CAGR of 5.9% during forecasting period 2026-2032.
3. What is scope of the Global market report?
Ans: Global Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. Who are the key players in Global market?
Ans: The important key players in the Global Market are – Shire Plc., AstraZeneca, Eli Lilly and Company, Merck KGaA, Sanofi, Pfizer, Amgen Inc., Biogen, Novartis AG, Actelion, Daiichi Sankyo, Boehringer Ingelheim International GmbH, Cipla Inc., AbbVie Inc., Bristol-Myers Squibb company, and Teva Pharmaceuticals.
5. What is the study period of this market?
Ans: The Global Market is studied from 2025 to 2032.
Table of Contents
Global Acquired Immuno Deficiency Syndrome (AIDS) Market
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives
2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Size, By Market Value (US$ Mn)
4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies
5. Supply Side and Demand Side Indicators
6. Global ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis and Forecast
6.1. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America
7. Global ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis and Forecast, By Drug-Class
7.1. Introduction and Definition
7.2. Key Findings
7.3. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Drug-Class
7.4. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Size (US$ Mn) Forecast, By Drug-Class
7.5. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis, By Drug-Class
7.6. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Attractiveness Analysis, By Drug-Class
8. Global ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis and Forecast, By Disease Indication
8.1. Introduction and Definition
8.2. Key Findings
8.3. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Disease Indication
8.4. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Size (US$ Mn) Forecast, By Disease Indication
8.5. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis, By Disease Indication
8.6. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Attractiveness Analysis, By Disease Indication
9. Global ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis, By Region
9.1. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Region
9.2. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Size (US$ Mn) Forecast, By Region
9.3. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Attractiveness Analysis, By Region
10. North America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis
10.1. Key Findings
10.2. North America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Overview
10.3. North America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Drug-Class
10.4. North America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
10.4.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
10.4.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
10.4.3. Combination Class Drugs
10.4.4. Entry & fusion inhibitors
10.4.5. Integrase inhibitors
10.5. North America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Disease Indication
10.6. North America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
10.6.1. Genetic Disorders
10.6.2. Rare cancers
10.6.3. Rare Blood Disorders
10.6.4. Autoimmune Disorders
10.6.5. Infectious Diseases
10.7. North America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Country
10.8. North America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Country
10.8.1. U.S.
10.8.2. Canada
10.8.3. Mexico
10.9. North America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis, By Country
10.10. U.S. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
10.10.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
10.10.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
10.10.3. Combination Class Drugs
10.10.4. Entry & fusion inhibitors
10.10.5. Integrase inhibitors
10.11. U.S. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
10.11.1. Genetic Disorders
10.11.2. Rare cancers
10.11.3. Rare Blood Disorders
10.11.4. Autoimmune Disorders
10.11.5. Infectious Diseases
10.12. Canada ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
10.12.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
10.12.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
10.12.3. Combination Class Drugs
10.12.4. Entry & fusion inhibitors
10.12.5. Integrase inhibitors
10.13. Canada ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
10.13.1. Genetic Disorders
10.13.2. Rare cancers
10.13.3. Rare Blood Disorders
10.13.4. Autoimmune Disorders
10.13.5. Infectious Diseases
10.14. Mexico ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
10.14.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
10.14.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
10.14.3. Combination Class Drugs
10.14.4. Entry & fusion inhibitors
10.14.5. Integrase inhibitors
10.15. Mexico ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
10.15.1. Genetic Disorders
10.15.2. Rare cancers
10.15.3. Rare Blood Disorders
10.15.4. Autoimmune Disorders
10.15.5. Infectious Diseases
10.16. North America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Attractiveness Analysis
10.16.1. By Drug-Class
10.16.2. By Disease Indication
10.17. PEST Analysis
10.18. Key Trends
10.19. Key Developments
11. Europe ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis
11.1. Key Findings
11.2. Europe ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Overview
11.3. Europe ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Drug-Class
11.4. Europe ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
11.4.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
11.4.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
11.4.3. Combination Class Drugs
11.4.4. Entry & fusion inhibitors
11.4.5. Integrase inhibitors
11.5. Europe ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Disease Indication
11.6. Europe ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
11.6.1. Genetic Disorders
11.6.2. Rare cancers
11.6.3. Rare Blood Disorders
11.6.4. Autoimmune Disorders
11.6.5. Infectious Diseases
11.7. Europe ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Country
11.8. Europe ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Country
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Sweden
11.8.7. CIS countries
11.8.8. Rest of Europe
11.9. Germany ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
11.9.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
11.9.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
11.9.3. Combination Class Drugs
11.9.4. Entry & fusion inhibitors
11.9.5. Integrase inhibitors
11.10. Germany ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
11.10.1. Genetic Disorders
11.10.2. Rare cancers
11.10.3. Rare Blood Disorders
11.10.4. Autoimmune Disorders
11.10.5. Infectious Diseases
11.11. U.K. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
11.11.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
11.11.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
11.11.3. Combination Class Drugs
11.11.4. Entry & fusion inhibitors
11.11.5. Integrase inhibitors
11.12. U.K. ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
11.12.1. Genetic Disorders
11.12.2. Rare cancers
11.12.3. Rare Blood Disorders
11.12.4. Autoimmune Disorders
11.12.5. Infectious Diseases
11.13. France ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
11.13.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
11.13.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
11.13.3. Combination Class Drugs
11.13.4. Entry & fusion inhibitors
11.13.5. Integrase inhibitors
11.14. France ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
11.14.1. Genetic Disorders
11.14.2. Rare cancers
11.14.3. Rare Blood Disorders
11.14.4. Autoimmune Disorders
11.14.5. Infectious Diseases
11.15. Italy ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
11.15.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
11.15.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
11.15.3. Combination Class Drugs
11.15.4. Entry & fusion inhibitors
11.15.5. Integrase inhibitors
11.16. Italy ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
11.16.1. Genetic Disorders
11.16.2. Rare cancers
11.16.3. Rare Blood Disorders
11.16.4. Autoimmune Disorders
11.16.5. Infectious Diseases
11.17. Spain ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
11.17.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
11.17.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
11.17.3. Combination Class Drugs
11.17.4. Entry & fusion inhibitors
11.17.5. Integrase inhibitors
11.18. Spain ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
11.18.1. Genetic Disorders
11.18.2. Rare cancers
11.18.3. Rare Blood Disorders
11.18.4. Autoimmune Disorders
11.18.5. Infectious Diseases
11.19. Sweden ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
11.19.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
11.19.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
11.19.3. Combination Class Drugs
11.19.4. Entry & fusion inhibitors
11.19.5. Integrase inhibitors
11.20. Sweden ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
11.20.1. Genetic Disorders
11.20.2. Rare cancers
11.20.3. Rare Blood Disorders
11.20.4. Autoimmune Disorders
11.20.5. Infectious Diseases
11.21. CIS countries ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
11.21.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
11.21.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
11.21.3. Combination Class Drugs
11.21.4. Entry & fusion inhibitors
11.21.5. Integrase inhibitors
11.22. CIS countries ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
11.22.1. Genetic Disorders
11.22.2. Rare cancers
11.22.3. Rare Blood Disorders
11.22.4. Autoimmune Disorders
11.22.5. Infectious Diseases
11.23. Rest of Europe ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
11.23.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
11.23.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
11.23.3. Combination Class Drugs
11.23.4. Entry & fusion inhibitors
11.23.5. Integrase inhibitors
11.24. Rest of Europe ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
11.24.1. Genetic Disorders
11.24.2. Rare cancers
11.24.3. Rare Blood Disorders
11.24.4. Autoimmune Disorders
11.24.5. Infectious Diseases
11.25. Europe ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Attractiveness Analysis
11.25.1. By Disease Indication
11.25.2. By Drug-Class
11.26. PEST Analysis
11.27. Key Trends
11.28. Key Developments
12. Asia Pacific ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis
12.1. Key Findings
12.2. Asia Pacific ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Overview
12.3. Asia Pacific ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Drug-Class
12.4. Asia Pacific ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
12.4.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
12.4.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
12.4.3. Combination Class Drugs
12.4.4. Entry & fusion inhibitors
12.4.5. Integrase inhibitors
12.5. Asia Pacific ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Disease Indication
12.6. Asia Pacific ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
12.6.1. Genetic Disorders
12.6.2. Rare cancers
12.6.3. Rare Blood Disorders
12.6.4. Autoimmune Disorders
12.6.5. Infectious Diseases
12.7. Asia Pacific ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Country
12.8. Asia Pacific ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Country
12.8.1. China
12.8.2. India
12.8.3. Japan
12.8.4. South Korea
12.8.5. Australia
12.8.6. ASEAN
12.8.7. Rest of Asia Pacific
12.9. Asia Pacific ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis, By Country
12.10. China ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
12.10.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
12.10.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
12.10.3. Combination Class Drugs
12.10.4. Entry & fusion inhibitors
12.10.5. Integrase inhibitors
12.11. China ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
12.11.1. Genetic Disorders
12.11.2. Rare cancers
12.11.3. Rare Blood Disorders
12.11.4. Autoimmune Disorders
12.11.5. Infectious Diseases
12.12. India ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
12.12.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
12.12.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
12.12.3. Combination Class Drugs
12.12.4. Entry & fusion inhibitors
12.12.5. Integrase inhibitors
12.13. India ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
12.13.1. Genetic Disorders
12.13.2. Rare cancers
12.13.3. Rare Blood Disorders
12.13.4. Autoimmune Disorders
12.13.5. Infectious Diseases
12.14. Japan ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
12.14.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
12.14.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
12.14.3. Combination Class Drugs
12.14.4. Entry & fusion inhibitors
12.14.5. Integrase inhibitors
12.15. Japan ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
12.15.1. Genetic Disorders
12.15.2. Rare cancers
12.15.3. Rare Blood Disorders
12.15.4. Autoimmune Disorders
12.15.5. Infectious Diseases
12.16. South Korea ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
12.16.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
12.16.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
12.16.3. Combination Class Drugs
12.16.4. Entry & fusion inhibitors
12.16.5. Integrase inhibitors
12.17. South Korea ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
12.17.1. Genetic Disorders
12.17.2. Rare cancers
12.17.3. Rare Blood Disorders
12.17.4. Autoimmune Disorders
12.17.5. Infectious Diseases
12.18. Australia ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
12.18.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
12.18.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
12.18.3. Combination Class Drugs
12.18.4. Entry & fusion inhibitors
12.18.5. Integrase inhibitors
12.19. Australia ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
12.19.1. Genetic Disorders
12.19.2. Rare cancers
12.19.3. Rare Blood Disorders
12.19.4. Autoimmune Disorders
12.19.5. Infectious Diseases
12.20. ASEAN ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
12.20.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
12.20.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
12.20.3. Combination Class Drugs
12.20.4. Entry & fusion inhibitors
12.20.5. Integrase inhibitors
12.21. ASEAN ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
12.21.1. Genetic Disorders
12.21.2. Rare cancers
12.21.3. Rare Blood Disorders
12.21.4. Autoimmune Disorders
12.21.5. Infectious Diseases
12.22. Rest of Asia Pacific ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
12.22.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
12.22.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
12.22.3. Combination Class Drugs
12.22.4. Entry & fusion inhibitors
12.22.5. Integrase inhibitors
12.23. Rest of Asia Pacific ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
12.23.1. Genetic Disorders
12.23.2. Rare cancers
12.23.3. Rare Blood Disorders
12.23.4. Autoimmune Disorders
12.23.5. Infectious Diseases
12.24. Asia Pacific ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Attractiveness Analysis
12.24.1. By Drug-Class
12.24.2. By Disease Indication
12.25. PEST Analysis
12.26. Key Trends
12.27. Key Developments
13. Middle East & Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis
13.1. Key Findings
13.2. Middle East & Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Overview
13.3. Middle East & Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Drug-Class
13.4. Middle East & Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
13.4.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
13.4.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
13.4.3. Combination Class Drugs
13.4.4. Entry & fusion inhibitors
13.4.5. Integrase inhibitors
13.5. Middle East & Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Disease Indication
13.6. Middle East & Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
13.6.1. Genetic Disorders
13.6.2. Rare cancers
13.6.3. Rare Blood Disorders
13.6.4. Autoimmune Disorders
13.6.5. Infectious Diseases
13.7. Middle East & Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Country
13.8. Middle East & Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Country
13.8.1. GCC Countries
13.8.2. South Africa
13.8.3. Nigeria
13.8.4. Egypt
13.8.5. Rest of Middle East & Africa
13.9. Middle East & Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis, By Country
13.10. GCC Countries ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
13.10.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
13.10.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
13.10.3. Combination Class Drugs
13.10.4. Entry & fusion inhibitors
13.10.5. Integrase inhibitors
13.11. GCC Countries ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
13.11.1. Genetic Disorders
13.11.2. Rare cancers
13.11.3. Rare Blood Disorders
13.11.4. Autoimmune Disorders
13.11.5. Infectious Diseases
13.12. South Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
13.12.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
13.12.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
13.12.3. Combination Class Drugs
13.12.4. Entry & fusion inhibitors
13.12.5. Integrase inhibitors
13.13. South Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
13.13.1. Genetic Disorders
13.13.2. Rare cancers
13.13.3. Rare Blood Disorders
13.13.4. Autoimmune Disorders
13.13.5. Infectious Diseases
13.14. Nigeria ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
13.14.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
13.14.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
13.14.3. Combination Class Drugs
13.14.4. Entry & fusion inhibitors
13.14.5. Integrase inhibitors
13.15. Nigeria ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
13.15.1. Genetic Disorders
13.15.2. Rare cancers
13.15.3. Rare Blood Disorders
13.15.4. Autoimmune Disorders
13.15.5. Infectious Diseases
13.16. Egypt ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
13.16.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
13.16.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
13.16.3. Combination Class Drugs
13.16.4. Entry & fusion inhibitors
13.16.5. Integrase inhibitors
13.17. Egypt ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
13.17.1. Genetic Disorders
13.17.2. Rare cancers
13.17.3. Rare Blood Disorders
13.17.4. Autoimmune Disorders
13.17.5. Infectious Diseases
13.18. Rest of Middle East & Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
13.18.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
13.18.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
13.18.3. Combination Class Drugs
13.18.4. Entry & fusion inhibitors
13.18.5. Integrase inhibitors
13.19. Rest of Middle East & Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
13.19.1. Genetic Disorders
13.19.2. Rare cancers
13.19.3. Rare Blood Disorders
13.19.4. Autoimmune Disorders
13.19.5. Infectious Diseases
13.20. Middle East & Africa ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Attractiveness Analysis
13.20.1. By Drug-Class
13.20.2. By Disease Indication
13.21. PEST Analysis
13.22. Key Trends
13.23. Key Developments
14. South America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis
14.1. Key Findings
14.2. South America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Overview
14.3. South America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Drug-Class
14.4. South America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
14.4.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
14.4.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
14.4.3. Combination Class Drugs
14.4.4. Entry & fusion inhibitors
14.4.5. Integrase inhibitors
14.5. South America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Disease Indication
14.6. South America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
14.6.1. Genetic Disorders
14.6.2. Rare cancers
14.6.3. Rare Blood Disorders
14.6.4. Autoimmune Disorders
14.6.5. Infectious Diseases
14.7. South America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Value Share Analysis, By Country
14.8. South America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Country
14.8.1. Brazil
14.8.2. Colombia
14.8.3. Argentina
14.8.4. Rest of South America
14.9. South America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Analysis, By Country
14.10. Brazil ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
14.10.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
14.10.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
14.10.3. Combination Class Drugs
14.10.4. Entry & fusion inhibitors
14.10.5. Integrase inhibitors
14.11. Brazil ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
14.11.1. Genetic Disorders
14.11.2. Rare cancers
14.11.3. Rare Blood Disorders
14.11.4. Autoimmune Disorders
14.11.5. Infectious Diseases
14.12. Colombia ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
14.12.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
14.12.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
14.12.3. Combination Class Drugs
14.12.4. Entry & fusion inhibitors
14.12.5. Integrase inhibitors
14.13. Colombia ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
14.13.1. Genetic Disorders
14.13.2. Rare cancers
14.13.3. Rare Blood Disorders
14.13.4. Autoimmune Disorders
14.13.5. Infectious Diseases
14.14. Argentina ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
14.14.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
14.14.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
14.14.3. Combination Class Drugs
14.14.4. Entry & fusion inhibitors
14.14.5. Integrase inhibitors
14.15. Argentina ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
14.15.1. Genetic Disorders
14.15.2. Rare cancers
14.15.3. Rare Blood Disorders
14.15.4. Autoimmune Disorders
14.15.5. Infectious Diseases
14.16. Rest of South America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Drug-Class
14.16.1. Nucleoside Reverse Transcriptase Inhibitors(NRTIs)
14.16.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
14.16.3. Combination Class Drugs
14.16.4. Entry & fusion inhibitors
14.16.5. Integrase inhibitors
14.17. Rest of South America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Forecast, By Disease Indication
14.17.1. Genetic Disorders
14.17.2. Rare cancers
14.17.3. Rare Blood Disorders
14.17.4. Autoimmune Disorders
14.17.5. Infectious Diseases
14.18. South America ACQUIRED IMMUNO DEFICIENCY SYNDROME (AIDS) Market Attractiveness Analysis
14.18.1. By Drug-Class
14.18.2. By Disease Indication
14.19. PEST Analysis
14.20. Key Trends
14.21. Key Developments
15. Company Profiles
15.1. Market Share Analysis, By Company
15.2. Competition Matrix
15.2.1. Competitive Benchmarking of key players By price, presence, market share, Component, and R&D investment
15.2.2. New Product Launches and Product Enhancements
15.2.3. Market Consolidation
15.2.3.1. M&A By Regions, Investment and Component
15.2.3.2. M&A Key Players, Forward Integration and Backward Integration
15.3. Company Profiles: Key Players
15.3.1. Shire Plc.
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategy
15.3.1.5. Recent Developments
15.3.1.6. Development Footprint
15.3.2. AstraZeneca
15.3.3. Eli Lilly and Company
15.3.4. Merck KGaA
15.3.5. Sanofi
15.3.6. Pfizer
15.3.7. Amgen Inc.
15.3.8. Biogen
15.3.9. Novartis AG
15.3.10. Actelion
15.3.11. Daiichi Sankyo
15.3.12. Boehringer Ingelheim International GmbH
15.3.13. Cipla Inc.
15.3.14. AbbVie Inc.
15.3.15. Bristol-Myers Squibb company
15.3.16. Teva Pharmaceuticals
16. Primary key Insights